Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print          Annual reports

Tuesday 29 June, 2021

Alliance Pharma PLC

Appointment of Non-Executive Director

RNS Number : 3940D
Alliance Pharma PLC
29 June 2021
 

 


   

For immediate release    29 June 2021

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Appointment of Non-Executive Director

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Kristof Neirynck, a highly experienced consumer brands executive, will join the Group on 1 December 2021 as an independent Non-Executive Director.

 

Kristof is currently Group Vice-President and Chief Marketing Officer Global Brands at Walgreens-Boots-Alliance (WBA), a global leader in retail pharmacy. He brings almost 20 years of international consumer brand experience including complex omni-channel business models, direct-to-consumer strategies and cross border e-commerce into China.

 

Kristof started his career in 2002 at Procter & Gamble in Belgium before moving to Procter & Gamble International in Switzerland in 2004 and working there for 11 years. He joined WBA in 2015 as Vice-President & Global Category Director Skin Care before being appointed to his current role in 2017. In this role, he has global responsibility for the portfolio of more than 20 WBA-owned brands across Beauty and Consumer Healthcare, representing more than $4bn in sales.

 

Following the departure of Nigel Clifford, who left the Group on 30 April 2021, Kristof's appointment brings the number of independent Non-Executive Directors back to four.

 

David Cook, Alliance Pharma's Chairman, said: "I am delighted to confirm the appointment of Kristof as a Non-Executive Director of Alliance and we look forward to his joining the Group on 1 December this year. Kristof brings outstanding operational and strategic experience of the consumer healthcare market, gained at global businesses. His international, omni-channel and marketing experience is highly complementary to the skillset of the existing Board members as we focus on the Group's international expansion."

 

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Kristof Leon Neirynck (43 years of age) has not been a director or partner of any companies during the five years preceding the date of this announcement. There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer


Andrew Franklin, Chief Financial Officer


www.alliancepharma.co.uk


Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele


Corporate Broking: James Black


 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams


Corporate Broking: Patrick Robb


 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABIGDLUDDDGBI

a d v e r t i s e m e n t